Alligator Bioscience publishes Annual Report for 2022
Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been publi ...
Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business update
Interim results from mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer exceed 50% Objective Response Rate, the trial passes pre-plan ...
Alligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business update
Patient enrolment for OPTIMIZE-1 Phase 2 study ahead of schedule with top-line data now brought forward to Q1 2024 and interim data on track ...
Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...
Alligator Bioscience AB: Interim report January–March 2022
A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...
Alligator Bioscience publishes Annual Report for 2021
Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2021 has been publi ...
Alligator Bioscience AB: Year End report January–December 2021
OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...
Alligator Bioscience AB: Interim report January–September 2021
First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...
Alligator Bioscience AB: Interim report January–June 2021
Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...